Jove
Visualize
Contact Us

Related Experiment Videos

Subclinical thyroid disease.

V Fatourechi1

  • 1Division of Endocrinology, Metabolism, Nutrition and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA.

Mayo Clinic Proceedings
|April 27, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Undetectable sensitive serum thyroglobulin (<0.1 ng/ml) in 163 patients with follicular cell-derived thyroid cancer: results of rhTSH stimulation and neck ultrasonography and long-term biochemical and clinical follow-up.

The Journal of clinical endocrinology and metabolism·2012
Same author

Subclinical thyroid dysfunction and the heart.

Annals of internal medicine·2003
Same author

Adverse effects of subclinical hyperthyroidism.

Lancet (London, England)·2001
Same author

A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy.

Ophthalmology·2001
Same author

Hypopituitarism caused by intrasellar aneurysms.

Mayo Clinic proceedings·2001
Same author

How to use the new sensitive thyrotropin assays.

Postgraduate medicine·2000
Same journal

37-Year-Old Woman With Jaundice.

Mayo Clinic proceedings·2026
Same journal

34-Year-Old Woman With An Unidentified Overdose.

Mayo Clinic proceedings·2026
Same journal

Use of Bronchoscopic Cryobiopsy in Evaluating Interstitial Lung Disease: Radiologic Predictors of Diagnostic Yield and Safety.

Mayo Clinic proceedings·2026
Same journal

Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

Mayo Clinic proceedings·2026
Same journal

RAAS Inhibition in the ICU: Stop, Continue, or Restart?

Mayo Clinic proceedings·2026
Same journal

Chronic Kidney Disease-In the Limelight, July 2026.

Mayo Clinic proceedings·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Subclinical thyroid disease, including incidentalomas, requires careful management. Treatment for subclinical hyperthyroidism is recommended for those over 60, while subclinical hypothyroidism management depends on thyroid-stimulating hormone levels and clinical factors.

Area of Science:

  • Endocrinology
  • Internal Medicine
  • Diagnostic Imaging

Background:

  • Subclinical thyroid disease encompasses asymptomatic abnormalities detected via imaging or lab tests.
  • Thyroid incidentalomas are non-palpable nodules found incidentally.
  • Nodules <1 cm without risk factors for thyroid cancer do not necessitate biopsy.

Purpose of the Study:

  • To define and outline management strategies for subclinical thyroid disease.
  • To differentiate between subclinical hyperthyroidism and hypothyroidism.
  • To provide guidance on biopsy and treatment decisions.

Main Methods:

  • Review of definitions for subclinical thyroid disease and incidentalomas.
  • Description of diagnostic criteria for subclinical hyperthyroidism and hypothyroidism.

Related Experiment Videos

  • Outline of treatment guidelines based on thyroid-stimulating hormone (TSH) levels and clinical factors.

    • Main Results:

    • Subclinical hyperthyroidism (suppressed TSH, normal thyroxine/triiodothyronine) poses risks to the heart and bones, warranting treatment in patients >60 years.
    • Subclinical hypothyroidism (mildly elevated TSH, normal thyroxine) is common.
    • Thyroxine therapy for subclinical hypothyroidism is indicated for TSH >10 mIU/L; individualized decisions are needed for TSH 5-10 mIU/L based on antibodies and clinical presentation.

    Conclusions:

    • Subclinical thyroid disease requires specific diagnostic criteria and management approaches.
    • Treatment decisions for subclinical thyroid disease should consider patient age, TSH levels, and other clinical factors.
    • Early detection and appropriate management of subclinical thyroid disease can mitigate potential adverse health outcomes.